ImmunologybioRxiv
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2
A. Barreiro, A. Prenafeta, G. Bech-Sabat…·Barr
This paper evaluates a recombinant RBD fusion heterodimer vaccine in mice, showing 100% efficacy against SARS-CoV-2 variants and neutralizing antibodies.
DOI 10.1016/j.isci.2023.106126